Association of TERT, OGG1, and CHRNA5 Polymorphisms and the Predisposition to Lung Cancer in Eastern Algeria
Table 4
Association between TERT, CHRNA5, and OGG1 polymorphisms and lung cancer risk, stratified by gender and age.
Population
Gene
Genotype
Cases/controlsa
ORAdj
CIAdj
Adj
Male
TERT rs2853669
TT
55/40
Ref
TC
40/32
0.76
0.74
(0.35-1.55)
0.43
CC
6/0
0.04
—
—
0.99
Dominant (TC+CC)
46/32
0.88
0.90
(0.43-1.86)
0.78
Recessive (TC+TT)
95/72
0.03
—
—
0.98
CHRNA5 rs16969968
GG
49/60
Ref
GA
51/65
0.88
0.92
(0.50–1.71)
0.80
AA
18/9
0.04
1.99
(0.70–6.26)
0.20
Dominant (GA+AA)
69/74
0.60
1.05
(0.58–1.90)
0.85
Recessive (GA+GG)
100/125
0.02
2.09
(0.82–5.88)
0.13
OGG1 rs1052133
CC
68/67
Ref
CG
42/51
0.43
0.80
(0.44-1.48)
0.47
GG
9/15
0.24
1.49
(0.44-5.52)
0.52
Dominant (CG+GG)
51/66
0.28
0.87
(0.48-1.56)
0.64
Recessive (CG+CC)
110/118
0.31
1.51
(0.47-5.36)
0.48
Female
TERT rs2853669
TT
16/17
Ref
TC
9/4
0.20
2.49
(0.66-10.91)
0.19
CC
0/1
0.33
—
—
0.99
Dominant (TC+CC)
9/5
0.32
2.02
(0.56–7.97)
0.29
Recessive (TC+TT)
25/21
0.28
—
—
0.99
CHRNA5 rs16969968
GG
11/33
Ref
GA
13/40
0.95
1.03
(0.39-2.70)
0.94
AA
1/4
0.80
0.75
(0.02-8.22)
0.83
Dominant (GA+AA)
14/44
0.92
1.01
(0.39-2.62)
0.97
Recessive (GG+AA)
24/73
0.81
0.85
(0.03-7.46)
0.90
OGG1 rs1052133
CC
11/40
Ref
CG
12/32
0.51
1.06
(0.39-2.85)
0.89
GG
2/5
0.67
1.23
(0.14–7.25)
0.82
Dominant
14/37
0.48
1.06
(0.41-2.77)
0.89
Recessive
23/72
0.79
1.20
(0.16-6.24)
0.83
>60
TERT rs2853669
TT
32/16
Ref
TC
28/5
0.06
2.26
(0.72-7.97)
0.17
CC
3/0
0.22
—
—
0.99
Dominant (TC+CC)
31/5
0.04
2.49
(0.80-8.72)
0.12
Recessive (TC+TT)
60/21
0.30
—
—
0.99
CHRNA5 rs16969968
GG
31/16
Ref
GA
29/23
0.30
0.62
(0.26–1.43)
0.27
AA
12/2
0.15
2.83
(0.62–20.48)
0.22
Dominant (GA+AA)
42/93
0.52
1.26
(0.66–2.42)
0.46
Recessive (GG+AA)
64/159
0.36
1.22
(0.38–3.86)
0.72
OGG1 rs1052133
CC
38/15
Ref
CG
29/26
0.04
0.49
(0.21-1.11)
0.09
GG
5/0
0.16
—
—
0.99
Dominant (CG+GG)
34/26
0.09
0.58
(0.25-1.29)
0.18
Recessive (CG+CC)
67/41
0.08
—
—
0.98
<60
TERT rs2853669
TT
39/41
Ref
TC
21/31
0.34
0.67
(0.30-1.48)
0.33
CC
3/1
0.30
2.99
(0.33–65.93)
0.37
Dominant (TC+CC)
24/32
0.49
0.76
(0.34-1.63)
0.48
Recessive (TC+TT)
60/72
0.24
3.70
(0.41-82.55)
0.28
CHRNA5 rs16969968
GG
29/77
Ref
GA
35/82
0.67
1.26
(0.65–2.44)
0.48
AA
7/11
0.31
1.27
(0.35–4.48)
0.70
Dominant (GA+AA)
42/93
0.52
1.26
(0.66–2.42)
0.46
Recessive (GG+GA)
64/159
0.36
1.22
(0.38–3.86)
0.72
OGG1 rs1052133
CC
41/92
Ref
CG
25/57
0.95
1.33
(0.76–2.66)
0.41
GG
6/20
0.42
1.01
(0.30–3.20)
0.97
Dominant (CG+GG)
31/77
0.72
1.27
(0.67–2.44)
0.45
Recessive (CG+CC)
66/149
0.42
0.90
(0.27–2.75)
0.86
OR = odds ratio; CI = confidence interval; Adj = adjusted. OR and adjusted for smoking and gender. OR adjusted for age and smoking habit. aNumbers may not add up the total number of patients due to genotype failures.
